Suppliers and packagers for generic pharmaceutical drug: linaclotide

linaclotide

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811	NDA	Allergan, Inc.	0456-1201-04	1 BOTTLE in 1 CARTON (0456-1201-04) / 4 CAPSULE, GELATIN COATED in 1 BOTTLE	2012-09-08
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811	NDA	Allergan, Inc.	0456-1201-07	1 BOTTLE in 1 CARTON (0456-1201-07) / 7 CAPSULE, GELATIN COATED in 1 BOTTLE	2012-09-08
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811	NDA	Allergan, Inc.	0456-1201-30	1 BOTTLE in 1 CARTON (0456-1201-30) / 30 CAPSULE, GELATIN COATED in 1 BOTTLE	2012-09-08
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811	NDA	Allergan, Inc.	0456-1202-04	1 BOTTLE in 1 CARTON (0456-1202-04) / 4 CAPSULE, GELATIN COATED in 1 BOTTLE	2012-09-08

Linaclotide API and Excipient Supply Chain Landscape

Last updated: February 19, 2026

This report analyzes the current supply chain for linaclotide, a guanylate cyclase-C agonist used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. The analysis focuses on key suppliers of Active Pharmaceutical Ingredient (API) and critical excipients, their geographical distribution, and potential areas of supply chain risk.

Who Manufactures Linaclotide API?

The manufacturing of linaclotide API is primarily controlled by a limited number of specialized pharmaceutical chemical manufacturers. This concentration poses a potential risk for supply disruptions.

• Ipsen Pharma S.A.S.: As the originator company, Ipsen retains significant control over the linaclotide API supply. They utilize internal manufacturing capabilities and may also engage contracted manufacturing organizations (CMOs) for specific stages of production or increased capacity.
• Selected CMOs: While specific CMO partners are not publicly disclosed by Ipsen, the complex synthesis of linaclotide suggests the involvement of CMOs with expertise in peptide synthesis and small molecule manufacturing. These typically operate under strict quality agreements and intellectual property protections.

Geographic Distribution of API Manufacturing:

Historically, pharmaceutical API manufacturing has concentrated in regions with established chemical industries and cost advantages. For linaclotide API, manufacturing is likely to be located in:

• Europe: Given Ipsen's European origins, some manufacturing may occur within their European facilities or those of contracted partners.
• North America: The U.S. market is a primary consumer of linaclotide, suggesting potential domestic API production or significant reliance on secure North American supply chains.

Table 1: Linaclotide API Manufacturing Landscape

Company/Type	Primary Role	Geographic Focus (Likely)	Notes
Ipsen Pharma S.A.S.	Originator/Oversight	Europe, North America	Internal manufacturing and CMO management
Contracted Manufacturing Organizations (CMOs)	API Synthesis	Global (with regional concentrations)	Specialized peptide synthesis expertise required

What Are the Key Excipients Used in Linaclotide Formulations?

Linaclotide is formulated into oral capsules. The excipients used are standard pharmaceutical ingredients but their consistent availability from qualified suppliers is critical.

Common Excipients in Oral Solid Dosage Forms:

• Fillers/Diluents: These add bulk to the formulation, enabling accurate dosing.
  • Microcrystalline Cellulose (MCC): Widely used for its compressibility and flow properties. Major global suppliers include JRS Pharma and Avicel (DuPont Nutrition & Biosciences).
  • Lactose: Another common filler, though less frequently used in formulations where protein or peptide components are sensitive to pH or moisture. Key suppliers include DMV-Fonterra Excipients.
• Binders: These hold the tablet or granule ingredients together.
  • Hypromellose (HPMC): Commonly used in capsule formulations for its film-forming properties and controlled release characteristics. Major suppliers include Ashland and Shin-Etsu Chemical.
  • Povidone (PVP): Used as a binder in granulation processes. Suppliers include BASF.
• Disintegrants: These facilitate the breakdown of the capsule or tablet in the gastrointestinal tract.
  • Croscarmellose Sodium: A highly effective disintegrant. Suppliers include JRS Pharma and FMC Corporation.
  • Sodium Starch Glycolate: Another common disintegrant.
• Lubricants: These prevent sticking to manufacturing equipment.
  • Magnesium Stearate: The most prevalent lubricant in pharmaceutical manufacturing. Suppliers are numerous, including Mallinckrodt Pharmaceuticals and Ferro Corporation.
• Glidants: Improve powder flow.
  • Colloidal Silicon Dioxide: Also known as fumed silica. Suppliers include Evonik Industries and Cabot Corporation.

Capsule Shell Materials:

Linaclotide is typically delivered in hard-shell capsules. The primary materials are:

• Gelatin: Derived from animal collagen. Major global producers include Coni-Blanc (part of Capsugel), Rousselot, and Weishardt Group.
• Hypromellose (HPMC): Non-animal derived, often preferred for vegetarian or vegan formulations. Capsugel (Lonza) is a leading supplier of HPMC capsules.

Table 2: Key Excipient Suppliers for Linaclotide Formulations

Excipient Type	Common Examples	Primary Global Suppliers	Geographic Focus (Major Production)
Fillers/Diluents	Microcrystalline Cellulose	JRS Pharma, Avicel (DuPont)	Europe, North America, Asia
	Lactose	DMV-Fonterra Excipients	Europe
Binders	Hypromellose (HPMC)	Ashland, Shin-Etsu Chemical	Global
	Povidone (PVP)	BASF	Global
Disintegrants	Croscarmellose Sodium	JRS Pharma, FMC Corporation	Global
Lubricants	Magnesium Stearate	Mallinckrodt Pharmaceuticals, Ferro Corp.	Global
Glidants	Colloidal Silicon Dioxide	Evonik Industries, Cabot Corporation	Global
Capsule Shells (Gelatin)	Gelatin	Coni-Blanc, Rousselot, Weishardt Group	Europe, North America
Capsule Shells (HPMC)	HPMC Capsules	Capsugel (Lonza)	Global

What Are the Potential Supply Chain Risks?

The linaclotide supply chain, like many pharmaceutical supply chains, faces several inherent risks that can impact availability and cost.

API Manufacturing Concentration:

• Limited Number of Suppliers: As noted, the API is likely produced by a small pool of specialized manufacturers. A disruption at one facility, whether due to an accident, regulatory action, or geopolitical instability, could have significant ripple effects.
• Technical Complexity: The multi-step synthesis of peptides and complex small molecules requires specialized equipment, highly skilled personnel, and stringent quality control. This limits the number of entities capable of producing linaclotide API to the required pharmaceutical standards.
• Intellectual Property: Ipsen's patents on linaclotide and its manufacturing processes provide market exclusivity, further restricting the number of authorized API manufacturers.

Excipient Sourcing Vulnerabilities:

• Geographic Concentration of Raw Materials: While excipient production is more globally distributed than API manufacturing, the sourcing of key raw materials for certain excipients can be geographically concentrated. For example, the production of high-purity cellulose for MCC may rely on specific forestry resources or processing centers.
• Single-Source Dependence for Specialized Excipients: For certain niche excipients or specific grades of common excipients, a pharmaceutical company may rely on a single supplier. This creates a critical dependency.
• Quality and Regulatory Compliance: Excipient suppliers must meet stringent Good Manufacturing Practices (GMP) standards. A quality failure at an excipient supplier can lead to product recalls or manufacturing halts. The U.S. Food and Drug Administration (FDA) and other regulatory bodies actively monitor excipient quality.
• Logistical Challenges: The global nature of excipient sourcing means that transportation disruptions, trade tariffs, or port congestion can impact delivery timelines and costs.

Geopolitical and Economic Factors:

• Trade Wars and Tariffs: Changes in international trade policies can increase the cost of imported APIs or excipients, impacting the final drug price and supply chain economics.
• Political Instability: Regions with significant API or excipient manufacturing may experience political instability, leading to production interruptions or export restrictions.
• Currency Fluctuations: For companies sourcing materials globally, significant shifts in currency exchange rates can impact profitability and sourcing decisions.
• Pandemic Preparedness: The COVID-19 pandemic highlighted the fragility of global supply chains. Future health crises or widespread diseases can disrupt labor availability, manufacturing output, and transportation.

Regulatory Scrutiny:

• Evolving GMP Standards: Regulatory bodies continuously update GMP requirements. Suppliers must remain compliant, and any failure to do so can result in disqualification.
• Drug Master File (DMF) Updates: API and excipient manufacturers must maintain accurate and up-to-date DMFs with regulatory agencies. Delays or inaccuracies in DMF submissions can impede drug product approvals or continued manufacturing.

What Are the Strategies to Mitigate Supply Chain Risks?

Pharmaceutical companies employ several strategies to build resilience into their linaclotide supply chain.

Dual/Multi-Sourcing:

• API: For critical APIs, companies often qualify at least two independent API manufacturers. This is challenging for patented drugs where only the innovator or their authorized partners can produce the API. However, for off-patent drugs or where licensing agreements allow, multi-sourcing is a primary risk mitigation strategy.
• Excipients: Actively pursuing multiple qualified suppliers for all critical excipients is a standard practice. This involves rigorous vendor qualification processes, including audits and quality agreements.

Geographic Diversification:

• Supplier Location: Encouraging suppliers to have manufacturing sites in diverse geographic regions reduces the impact of localized disruptions.
• Inventory Management: Maintaining strategic safety stocks of critical APIs and excipients at geographically dispersed warehouses can buffer against short-term supply interruptions.

Contractual Agreements and Supplier Relationships:

• Long-Term Contracts: Negotiating long-term supply agreements provides price stability and guaranteed supply volumes.
• Robust Quality Agreements: Clearly defined quality agreements with suppliers outline responsibilities, specifications, change control procedures, and crisis management protocols.
• Supplier Audits and Monitoring: Regular audits and continuous monitoring of supplier performance, quality systems, and financial health are essential.

Vertical Integration:

• In some cases, pharmaceutical companies may choose to bring certain critical manufacturing steps in-house or acquire key suppliers to gain greater control over their supply chain. This is a significant capital investment.

Scenario Planning and Business Continuity:

• Developing detailed contingency plans for various disruption scenarios (e.g., natural disasters, regulatory shutdowns, raw material shortages) is crucial. This includes identifying alternative suppliers, transportation routes, and emergency production protocols.

Key Takeaways

The linaclotide supply chain is characterized by a concentrated API manufacturing landscape, primarily controlled by the originator company, Ipsen, and potentially a few select CMOs. Excipient supply is more diversified but still relies on key global manufacturers of common pharmaceutical ingredients like microcrystalline cellulose, hypromellose, and magnesium stearate. Potential risks include API supply disruptions due to manufacturing concentration, quality failures or shortages of critical excipients, geopolitical instability, and evolving regulatory requirements. Mitigation strategies involve dual/multi-sourcing of excipients, geographic diversification of suppliers, strong contractual agreements, robust quality management systems, and comprehensive business continuity planning.

Frequently Asked Questions

1. How does patent expiry affect the linaclotide supply chain?

Once linaclotide patents expire, generic manufacturers can enter the market. This typically leads to increased competition among API suppliers and potentially the emergence of new CMOs capable of producing the API. The demand for excipients may also increase as multiple generic products are launched.

2. What is the impact of geopolitical tensions on linaclotide API sourcing?

Geopolitical tensions can disrupt trade routes, lead to export restrictions, or cause instability in regions where API manufacturing is concentrated. This can result in increased lead times, higher costs, and potential shortages of linaclotide API.

3. Are there alternative excipients that can be used in linaclotide formulations?

While standard excipients are well-characterized, alternative excipients could be explored. However, any change in excipient requires significant formulation development, stability testing, and regulatory approval, which is a time-consuming and costly process.

4. What is the role of pharmacopeial standards in ensuring linaclotide supply chain quality?

Pharmacopeial standards, such as those set by the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), define the quality, purity, and potency for APIs and excipients. Adherence to these standards by all suppliers is critical for ensuring the safety and efficacy of linaclotide drug products.

5. How does the complexity of peptide synthesis influence API supplier selection?

Linaclotide is a peptide, and its synthesis is more complex than that of typical small molecules. This complexity requires specialized expertise, advanced manufacturing technologies, and stringent quality control measures, significantly limiting the pool of qualified API manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Specific URL for DMF information is dynamic and best found through a direct search on FDA.gov). [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA website] (Specific URL for GMP information is dynamic and best found through a direct search on EMA.europa.eu). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH Harmonised Guideline Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] Various publicly available company reports and industry directories for excipient suppliers. (Note: Specific reports are proprietary and not publicly cited here, but data reflects common industry knowledge).